Clinical review report:: Vedolizumab (Entyvio SC) Takeda Canada Inc. indication: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumor necrosis factor-alpha antagonist
The objective of this review is to perform a systematic review of the beneficial and harmful effects of vedolizumab subcutaneous injection for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, loss of response to, or were in...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
2020, July 2020
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review is to perform a systematic review of the beneficial and harmful effects of vedolizumab subcutaneous injection for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumour necrosis factor alpha antagonist |
|---|---|
| Physical Description: | 1 PDF file (107 pages) illustrations |